Drug Profile
IN AQUL 001
Latest Information Update: 26 Nov 2015
Price :
$50
*
At a glance
- Originator Intas Pharmaceuticals
- Class Sleep disorder therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Insomnia
Most Recent Events
- 26 Nov 2015 No recent reports on development identified - Phase-III for Insomnia (In adults, In the elderly) in India (PO)